Reset filters
  • 4 October 2007

Most patients on incompletely suppressive therapy maintain CD4 counts and stable viral loads

Read the article
  • 20 September 2007

ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced

Read the article
  • 19 September 2007

ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents

Read the article
  • 19 September 2007

ICAAC: Raltegravir shows sustained effect in highly treatment-experienced patients

Read the article
  • 19 September 2007

ICAAC: Vicriviroc safe, effective after 2 years, phase III studies start soon

Read the article
  • 12 September 2007

T-20 increases tipranavir levels but does not increase risk of liver side-effects

Read the article
  • 14 August 2007

IAS: Maraviroc produces best results when combined with another active drug

Read the article
  • 6 July 2007

TMC-125 and darunavir show strong effect in highly treatment-experienced, even without T-20

Read the article
  • 28 June 2007

Merck hopes for US integrase inhibitor license by October

Read the article

Receive the latest HIV research and conference news

Complete this form to receive regular email bulletins including the latest HIV research and conference news from aidsmap and/or updates from Terrence Higgins Trust.

Get regular email bulletins

Please let us know how you'd like to be contacted by ticking the options below.